cent secondary antibodies were diluted 1:200, with the exception of 1:2000, where Texas-red-labelled antibodies were diluted 1:700. Figures 2e–g and 3a, c–k represent individual confocal sections. The mouse monoclonal antibodies to tubulin and Myc were TUB2.1 (Sigma) and 9E10, respectively. Rabbit antibodies to RhoA (Santa Cruz) were diluted 1:100 times. Fluorescence intensity in individual cells was measured by a camera attached to the fluorescence microscope (Axiohot, Zeiss). A transfected cell was considered as highly expressing a protein if it required an exposure time of less than 10s. This value was observed in ~20% of the transfected cells. The rate of spontaneous cytokinesis failure, 1.8%, was estimated with control cells cotransfected with 1 µg pCAG-MycSTOP and 100 ng pEGFP-C1 (Clontech).

**Flow cytometry.** Two days after transfection, cells were trypsinized, fixed with 0.5% formaldehyde and permeabilized with 0.1% Triton X-100. They were stained with a combination of antibodies to RhoA and Myc and FITC-conjugated secondary antibodies, and for DNA with propidium iodide. The stained cells were subjected to flow cytometry on a FACS-Calibur (Becton Dickinson). Citron-transfected cells sensitive for FITC and mock-transfected cells were analysed for DNA content.

**Effect of Y-27632 on cytokinesis.** HeLa cells were synchronized with thymidine and nocodazole as described.6 After this procedure, ~60% of the cells appeared to have arrested in the M phase of the cell cycle. Y-27632 was added to the culture medium at various concentrations for the last 30 min of the nocodazole incubation. Cells were then washed three times and incubated with medium containing Y-27632 for 3 h. The percentage of mitotic cells that became binucleate was determined visually.

Received 5 May, accepted 17 June 1998.


**Supplementary information** is available on Nature's World-Wide Web site (http://www.nature.com).

**Acknowledgements.** We thank S. Yokomura and I. Mabuchi for critically reading the manuscript and H. A. Popel for editing it, H. Fuhrius and K. Nomura for technical assistance, and T. Arai, H. Nose and K. Okuyama for secretarial assistance. This work was supported in part by a grant from the Ministry of Education, Sciences, Sports and Culture of Japan and by a grant for the Human Frontier Science Program. P.M. was supported in part by the Ciba–Geigy Foundation.

Correspondence and requests for materials should be addressed to S.N. (e-mail: snara@iufm.med.kyoto-u.ac.jp). The nucleotide sequences encoding citron kinase have been deposited in GenBank under accession numbers AF070065 and AF070066.

---

**EEA1 links PI(3)K function to Rab5 regulation of endosome fusion**

Anne Simonsen†1, Roger Lippe‡##, Savvas Christoforidis##, Jean-Michel Gaulier†, Andreas Brech‡, Judy Callaghan†, Ban-Hock Toh†, Carol Murphy‡, Marino Zerial† & Harald Stenmark*.

* Department of Biochemistry, The Norwegian Radium Hospital, Montebello, N-0316 Oslo, Norway.
‡ EMBL, Meyerhofstrasse 1, D-69002 Heidelberg, Germany.
## EM-unit, Institute of Biology, PO Box 1050, Blindern, N-0316 Oslo, Norway.
† Department of Pathology and Immunology, Monash Medical School, Prahran, Victoria 3181, Australia.

# Max Planck Institute for Molecular Cell Biology and Genetics, Dresden, 01307, Germany.

† These authors contributed equally to this work.

GTases and lipid kinases regulate membrane traffic along the endocytic pathway by mechanisms that are not completely understood. Fusion between early endosomes requires phosphatidylinositol-3-OH kinase (PI(3)K) activity1,2 as well as the small GTPase Rab5 (ref. 3). Excess Rab5–GTP complex restores endosome fusion when PI(3)K is inhibited3. Here we identify the early-endosomal autotaggin EEA1 (refs 10–12) which binds the PI(3)K product phosphatidylinositol-3-phosphate, as a new Rab5 effector that is required for endosome fusion. The association of EEA1 with the endosomal membrane requires Rab5–GTP and PI(3)K activity, and excess Rab5–GTP stabilizes the membrane association of EEA1 even when PI(3)K is inhibited. The identification of EEA1 as a direct Rab5 effector provides a molecular link between PI(3)K and Rab5, and its restricted distribution to early endosomes10 indicates that EEA1 may confer directionality to Rab5-dependent endocytic transport.

EEA1 binds to phosphatidylinositol-3-phosphate (PtdIns(3)-P)11,12 and localizes together with Rab5 on endosomes10,12,13. Because a GTP-hydrolysis-deficient mutant of Rab5 can counteract the effect of the PI(3)K inhibitor wortmannin on endosome fusion5,8, we determined whether EEA1 might physically interact with Rab5. Using the yeast two-hybrid system (Table 1), we first found that wild-type Rab5 and a mutant with preferential affinity for GDP, Rab5<sub>SMN</sub>, in which serine 34 is converted to asparagine, showed minimal interaction with EEA1. Remarkably, the GTPase-deficient mutant Rab5<sub>S279</sub> interacted strongly with EEA1, indicating that the GTP-bound form of Rab5 may recognize EEA1. We detected no interaction between EEA1 and the corresponding GTPase-deficient mutants of other Rab proteins (Rab3A<sup>S81L</sup>, Rab3C<sup>S81L</sup>, Rab4A<sup>S271L</sup>, Rab4B<sup>S271L</sup>, Rab6<sup>R271L</sup>, Rab8<sup>R271L</sup> and Rab11<sup>R271L</sup>) (Table 1), indicating that EEA1 interacts specifically with Rab5.

A deletion analysis showed that both amino- and carboxy-terminal EEA1 fragments (EEA1-NT and EEA1-CT, respectively; Fig. 1a) can interact with Rab5<sub>S279L</sub> in the two-hybrid system (Table 1). We first found that EEA1-NT (Fig. 1a) interacts with

---

‡ Present address: University of Ioannina Medical School, 45110 Ioannina, Greece.
Rab5Q79L and not with Rab5S34N. This interaction presumably involves the C2-H2 zinc-finger motif of EEA1, as a point mutation in this motif (producing EEA1-NTΔC46S) abolished the interaction with Rab5Q79L, and a small fragment containing the zinc finger (EEA1Δ91) retained the ability to interact. We further found that, like EEA1-NT, EEA1-CT, which contains a PtdIns(3)P-binding FYVE finger12, interacts with Rab5Q79L, but not with Rab5S34N. The entire FYVE finger could be removed with only a weak reduction in Rab5Q79L binding (Table 1). The minimal Rab-binding region of EEA1-CT resides within residues 1,277–1,348, which constitute the domain immediately N-terminal of the FYVE finger. The region encompassing amino-acid residues 1,306–1,340 of EEA1 is 29% identical and 43% similar to the Rab5-binding region of the Rab5 effector Rabaptin-5 (results not shown), indicating that the Rab5-binding regions of EEA1-CT and Rabaptin-5 may be structurally related.

We next confirmed the Rab5–EEA1 interactions biochemically. EEA1 from bovine brain cytosol bound specifically to immobilized Rab5 fused to maltose-binding protein (MBP–Rab5). We detected binding only in the presence of the non-hydrolysable GTP analogue GTP-γS, and not in the presence of GDP or the absence of nucleotide (Fig. 1b). In agreement with the two-hybrid data, we detected only background-level interaction of EEA1 with MBP–Rab4 and with MBP–Rab6, even in the presence of GTP-γS. Moreover, recombinant His6–EEA1 protein bound to an immobilized glutathione S-transferase (GST)–Rab5 fusion protein in the GTPγS-bound form, but not in the GDP-bound form (Fig. 1c), showing that the interaction is direct and independent of other cytosolic factors. Finally, we also demonstrated GTPγS-specific interactions between GST–Rab5 and MBP–EEA1-NT (Fig. 1d) or MBP–EEA1-CT (Fig. 1e), confirming the results from the two-hybrid assays.

Next we determined whether EEA1 functions in early-endosome fusion. Expression of Rab5Q79L leads to the expansion of early endosomes in BHK cells because of increased fusion activity (Fig. 2a)13. Although the expression of Myc-epitope-tagged EEA1-NT with Rab5Q79L had no effect (results not shown), the coexpression of Myc-tagged EEA1-CT (Fig. 2b) counteracted the activity of the Rab5 mutant, resulting in the clustering of small endocytic structures (Fig. 2b, inset) often located in the periphery of the cell. In contrast, the FYVE-finger mutant EEA1-CTΔC1358S, which does not bind to endosomes15, did not affect the expansion of early endosomes (Fig. 2c), indicating that the effect of EEA1-CT requires its binding to endosomes. We studied the effect of EEA1-CT on early endosomes under normal conditions (that is, in the absence of the stimulatory Rab5 mutant) by electron microscopy. Cells expressing EEA1-CT contained many small, early-endocytic profiles (Fig. 2d), which were significantly smaller than the early endosomes of uninfected cells (Fig. 2e). These results indicate that the expression of EEA1-CT affects the size of normal as well as Rab5Q79L-containing early endosomes.

To determine whether EEA1-CT inhibits early-endosome fusion directly, we used an in vitro endosome fusion assay based on the detection of complexes formed between ligands internalized into two separate early endosome populations6,16. We prepared cytosol from baby hamster kidney (BHK) cells overexpressing EEA1-CT or EEA1-CTΔC1358S and tested this cytosol in the fusion assay in the presence of cytosol from HeLa cells. The fusion activity was cytosol-dependent (Fig. 3a). We detected 60% inhibition of fusion when early endosomes were incubated in the presence of cytosol containing EEA1-CT, but not in the presence of cytosol containing EEA1-CTΔC1358S. An anti-EEA1 serum, but not its corresponding preimmune serum, inhibited early-endosome fusion by ~80% when added directly to the fusion reaction (Fig. 3b). Addition of the peptide against which the antiserum had been raised completely rescued this inhibition, indicating that the blocking effect of the antibodies was specific. Depletion of EEA1 from cytosol caused a
somewhat lower inhibition of fusion (50–70%), and this effect could be rescued on addition either of an EEA1-enriched fraction purified from cytosol or of recombinant EEA1 (Fig. 3b). These data indicate that EEA1 is required for homotypic early-endosome fusion.

The observation that EEA1 functions in endosome fusion is intriguing in view of previous findings that PI(3)K activity is required both for endosome fusion5–7,17 and for EEA1 binding to endosomes11,12. We found that in vitro endosome fusion was inhibited ~70% by 100 nM wortmannin, a PI(3)K inhibitor. This inhibition was counteracted by Rab5 (incorporated as an XTP-binding mutant, Rab5D136N, loaded with XTP–gS or XTP18), which stimulated fusion strongly (Fig. 3b). The effect of Rab5 (–XTP) is probably the result of mass action of activated Rab5 rather than an effect of neutralization of the inhibition by wortmannin9. The finding that EEA1 depletion from cytosol only partially inhibited fusion (Fig. 3b) could be explained by the presence of residual EEA1 on the endosome membrane, in agreement with previous localization studies10. Fusion after EEA1 depletion and wortmannin treatment was less than after either treatment alone, indicating that the two treatments had an additive effect (Fig. 3b). The presence of Rab5–XTP restored fusion up to only 35% of the basal level under these conditions. Rab5–XTP–gS had a similar effect to Rab5–XTP (results not shown). The effect of Rab5–XTP and Rab5–XTP–gS is probably due to their action on residual EEA1 present in the fusion reaction. These results show that EEA1 is essential for Rab5-dependent endosome fusion, and that its activity is regulated by PI(3)K.

Given that EEA1 can bind to PtdIns(3)P as well as to activated Rab5, we determined whether Rab5–GTP can counteract the inhibition of early-endosome fusion induced by wortmannin by stabilizing EEA1 on the membrane. For this purpose we used Madin–Darby canine kidney (MDCK) cells expressing Rab5Q79L (Fig. 4)19. Although EEA1 was abundant in the cytosol (Fig. 4, lane 1) as well as in the membrane fraction (lane 2) of untransfected cells, most EEA1 was membrane-bound in Rab5Q79L-expressing cells (lanes 5, 6). Most important, on treatment with wortmannin, EEA1 efficiently dissociated from the membranes of untransfected cells (lanes 3, 4)11,12, whereas a significant fraction remained membrane-bound in the Rab5Q79L-expressing cells (lanes 7, 8). These data indicate that EEA1 binding to endosomes is dependent on PtdIns(3)P as well as on Rab5–GTP and that the presence of
activated Rab5 on the membrane can compensate for the lack of PtdIns(3)P in the presence of wortmannin.

The findings that EEA1 binds to activated Rab5 and regulates Rab5-dependent membrane fusion establish EEA1 as a new Rab5 effector. The two Rab5 effectors, EEA1 and Rabaptin-5 (ref. 20), are likely to have distinct functions; they are structurally different, and EEA1 is much more abundant than Rabaptin-5 on early endosomes.21,22 Because Rab5 is found not only on early endosomes but also at the plasma membrane and on clathrin-coated vesicles, other molecules are needed to confer directionality to Rab5-dependent membrane fusion. The restricted localization of EEA1 to early endosomes indicates that it may fulfill such a role.

The following model may explain our results. EEA1 may be recruited initially to early endosomes through binding to Rab5–GTP, and may then be stabilized further on the membrane by interaction of its FYVE finger with PtdIns(3)P. As the affinity of EEA1 for either of these components may be low, or because the components are labile, the binding of EEA1 to membranes would be inefficient in the absence of either Rab5–GTP or PtdIns(3)P. Our model predicts that the presence of either Rab5–GTP or PtdIns(3)P would be sufficient to recruit EEA1 to membranes if present in excessive amounts. This can be seen in the presence of excess Rab5–GTP (Fig. 4) and in experiments using liposomes (with excess PtdIns(3)P).11,12 Our results indicate that one important function of PI(3)K in the endocytic pathway may be to ensure the efficient attachment of the new Rab5 effector EEA1 to membranes. EEA1 may therefore be the first molecular link between PI(3)K and Rab5 in endocytic membrane traffic.

Methods
Antibodies and recombinant proteins. Anti-EEA1 was obtained by immunizing a rabbit with a peptide corresponding to the 16 N-terminal residues of EEA1 coupled to diphtheria toxoid. The antiserum was affinity-purified on recombinant MBP–EEA1–NT immobilized on Affi-Gel (Bio-Rad). For expression of GST–Rab5, Rab5 complementary DNA was cloned into pGEX-5x-3 (Pharmacia). In order to express His6–EEA1 in insect cells, we cloned Myc–EEA113 into pFAST-Bac-HTa (Gibco-BRL) and constructed a recombinant baculovirus according to the manufacturer’s instructions. For expression of MBP–EEA1–NT and MBP–EEA1–CT, we cloned the respective EEA1 constructs into pMAL-C2 (New England Biolabs). The EEA1 constructs were overexpressed in E. coli BL-21(DE3) cells. Expression and protein purification were according to the manufacturer’s instructions.

Measurement of protein–protein interactions with the yeast two-hybrid system. Yeast two-hybrid constructs were prepared in the ‘bait’ vector pLexA/pBTM116 (ref. 23) and the ‘prey’ vector pGAD-GH (Clontech) using Rab5 (ref. 21) and EEA1 (ref. 10) sequences with the indicated mutations. L40 yeast reporter cells25 were transformed as indicated in Table 1, and liquid β-galactosidase assays25 were done on duplicate transformants.

Rab5 affinity chromatography. For binding of cytosolic EEA1, MBP–Rab5 was coupled to Affi-Gel 15 (Bio-Rad) and then loaded with GDP or GTP–S. The beads were further incubated with a 0–40% (NH4)2SO4-precipitated fraction of bovine brain cytosol for 15 h at 4°C, and bound proteins were analysed by SDS–PAGE and immunoblotting with anti-EEA1 antibodies. To detect binding of recombinant EEA1, glutathione–agarose beads (Pharmacia) were incubated in the absence or presence of GST–Rab5 (2 μM) for 1 h at 37°C in a buffer containing 10 μM GDP or GTP–S. Recombinant His6–EEA1 (600 nM), MBP–EEA1–NT (1 μM) or MBP–EEA1–CT (43 nM) was added to the beads for 1 h at 4°C in the presence of 10 μg ml–1 albumin. Bound

Figure 3 EEA1 is required for early endosome fusion in vitro. Homotypic early-endosome fusion in the presence of (a) cytosol from BHK cells transfected with EEA1–GFP or EEA1–GFPmut or (b) preimmune serum, anti-EEA1 serum, anti-EEA1 serum + EEA1 N-terminal peptide added, EEA1-depleted HeLa cell cytosol in the absence or presence of recombinant His6–EEA1, EEA1-enriched cytosolic fraction, or HeLa cell cytosol incubated with wortmannin in the absence or presence of Rab5Q79L–XTP or Rab5Q79L–XTP (75 nM). Note that the four right-most columns of panel b all represent fusion experiments done in the presence of wortmannin. All fusion activities were calculated as a percentage of that occurring in the presence of cytosol and an ATP-regeneration system (basal fusion). This fusion was typically 5–10% of maximal fusion, defined as the signal detected in the presence of Triton X-100. Fusion in the absence of ATP was less than 10% of basal fusion (data not shown). Error bars represent deviations between duplicates. Note the different scale in a and b.

Figure 4 The membrane association of EEA1 is regulated by Rab5 and PI(3)K. Wild-type (lanes 1–4) or Rab5Q79L–transfected (lanes 5–8) MDCK I cells in 9-cm plastic dishes were incubated for 30 min at 37°C in the absence (lanes 1, 2, 5, 6) or presence (lanes 3, 4, 7, 8) of 100 nM wortmannin. The cells were then homogenized, and postnuclear supernatants were centrifuged at 100,000 for 30 min (ref. 20). The pellet (lanes 1, 3, 5 and 7) and supernatant fractions (lanes 2, 4, 6 and 8) were analysed by SDS–PAGE followed by immunoblotting with anti-EEA1 antibodies.
Transcriptional activators direct histone acetyltransferase complexes to nucleosomes

Rhea T. Utley*, Keiko Ikeda†, Patrick A. Grant†, Jacques Côté*, David J. Steger*, Anton Eberharter*, Sam John* & Jerry L. Workman*

* Howard Hughes Medical Institute, Department of Biochemistry and Molecular Biology and the Center for Gene Regulation, The Pennsylvania State University, University Park, Pennsylvania 16802-5000, USA
† Department of Biology, Ichi Medical School, Minamikawachi, Kawachi, Tochigi 329-04, Japan
‡ Laval University Cancer Research Center, Hôtel-Dieu de Québec, Québec G1R-2J6, Canada

Transcriptional co-activators were originally identified as proteins that act as intermediaries between upstream activators and the basal transcription machinery. The discovery that co-activators such as Tetrhyamina and yeast Gcn5, as well as human p300/CBP, pCAB, SRC-1, ACO2 and TAFII250, can acetylate histones suggests that activators may be involved in targeting acetylation activity to promoters. Several histone deacetylases have been linked to transcriptional co-repressor proteins, suggesting that the action of both acetylases and deacetylases is important in the regulation of many genes. Here we demonstrate the binding of two native yeast histone acetyltransferase (HAT) complexes to the herpesvirus VP16 activation domain and the yeast transcriptional activator Gcn4, and show that it is their interaction with the VP16 activation domain that targets Gal4–VP16-bound nucleosomes for acetylation. We find that Gal4–VP16-driven transcription from chromatin templates is stimulated by both HAT complexes in an acetyl CoA-dependent reaction. Our results demonstrate the targeting of native HAT complexes by a transcription-activation domain to nucleosomes in order to activate transcription.

We previously identified four multisubunit native yeast HAT complexes. Two of these complexes, SAGA and Ada, preferentially acetylate nucleosomal histone H3 and contain Gcn5 as the catalytically active histone acetyltransferase subunit. SAGA (for Spt-Ada-Gcn5-acetyltransferase) is an 1,800 KDa complex which also contains Ada2, Ada3, Ada5, Spt20, Spt3 and Spt7 (ref. 2) explaining the functional link between the Ada and Spt classes of transcription regulator. The 800K Ada complex contains Ada2 and Ada3 as well as Gcn5, but none of the Spt proteins. Two HATs, formerly termed complex 2, which acetylates histones H4 and H2A, and complex 3, with a substrate preference for histone H3 (ref. 2), were purified and named NuA4 (for nucleosomal acetyltransferase of histone H4) and NuA3, respectively.

Acetylation of histone H3 is stimulated specifically in the promoter regions of Gcn5-dependent genes, indicating that promo-